Download PDFPDF

Mitomycin C for pterygium: long term evaluation
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Mitomycin C for pterygium: long term evaluation
    • Dennis S.C. Lam, Professor and Doctor
    • Other Contributors:
      • Hunter K.L. Yuen, Robert F. Lam, Dennis S.C. Lam

    Dear Editor

    We read with interest for the article by Raiskup et al. on the long term evaluation on mitomycin C (MMC) for pterygium.[1] It seems that the usage MMC in pterygium surgery is relatively safe in the long term.

    Overdosge of MMC eyedrops may be associated with potential serous side effects such as corneal perforation.[2] In this regards, we would like to point out a major typo in the Abstr...

    Show More
    Conflict of Interest:
    None declared.